진단 검사의학과와 중복되는 검사들의 결과 비교, 분석 (TSH, $FT_4$, AFP, CEA, PSA)

문기춘,권원현,김혜숙,이인원,Moon, Ki-Choon,Kwon, Won-Hyun,Kim, Hye-Sook,Lee, In-Won 대한핵의학기술학회 2009 핵의학 기술 Vol.13 No.3

Purpose: Nowadays, NM (in vitro lab) and LM (TLA lab) are overlaped in almost all tests. in this case, how can NM develop continually in a keen competition with LM. we studied to find out current situation and problems after comparing NM with LM. Then, to improve our technic. Methods and meterials: We studied from October 2008 to February 2009 at department of nuclear medicine Seoul National University Bundang Hospital visited 108 patients. We assayed TSH, $FT_4$ by Ria-mat{TSH (n=23), $FT_4$ (n=19)} and AFP, CEA, PSA by manual. {AFP (n=24), CEA (n=31), PSA (n=31)}. On the other hand, LM was measured by TLA system. Results: NM was similar to LM (value of AFP), NM<LM (value of CEA), NM>LM (value of PSA,TSH), NM$\leqq$LM (value of $FT_4$ in range 0.01~1.00 ng/mL), NM$\geqq$LM (value of $FT_4$ in range 1.00~6.00 ng/mL) Conclusions: There was no test which result showed big difference remarkably, but several tests have some difference totally or partly. It means that there is possibility to judge wrongly (normal patient->abnormal, abnormal->normal). So, we need to consider always when we report the result.

AFP 검사방법 단축에 관한 고찰

문기춘,권원현,김정인,이인원,Moon, Ki Choon,Kwon, Won Hyun,Kim, Jung In,Lee, In Won 대한핵의학기술학회 2013 핵의학 기술 Vol.17 No.1

AFP검사에 있어서 본원은 Immunotech사의 시약을 사용하고 있고 방법은 2 step법(IRMA)이다. 본원 내원환자 31명의 샘플을 대상으로 다소 번거로운 2step법을 1step법으로 간소화 할 수 있는지 비교실험을 하였다. 본법, 변법1(1step 45분), 변법2(1step 60분)의 상관계수와 회귀식, 정밀도, 회수율, 민감도, Hook effect를 확인하였다. 저, 중, 고역가 검체의 측정내 정밀도는 변법1은 3.05%, 3.43%, 1.68% 변법2는 5.00%, 3.69%, 1.97% 측정간 정밀도 는 변법 1은 3.91%, 2.38%, 0.82 % 변법2는 3.14%, 3.71%,1.85% 였다. 분석적민감도는 0.1 IU/mL 였고 직선성은 우수하였다. 상관관계는 각각 y=0.9293x+2.7356 ($R^{2}=0.9999$), y=0.9193x+4.1002 ($R^{2}=0.9993$) 이었다. 2,000 IU/mL 미만에 서는 Hook effect가 나타나지 않았지만 고농도에서는 Hook effect가 나타났다. 이 비교실험을 종합해 보면 본법과 변법1, 변법2 모두 상관관계, 정밀도, 회수율, 민감도 등이 우수함을 알 수 있다. 하지만, 고농도에서 Hook effect가 나타나 완전히 대체해서 사용하기에는 문제가 있다고 사료 된다. 다만, 정상인이 거의 대부분인 건강검진검사에서는 유용하게 사용될 수 있을 것으로 판단된다. Purpose: The Immunotech AFP is a widely used test in 14 hospitals(RIA QC establishments: 46) as a liver tumor marker. Normally, the test takes 45 minutes including complicated 2 step method. We evaluated the possibility of 1 step method and suitable test time. Materials and Methods: Samples of 31 patients in SNUBH were used as subject. We evaluated the sensitivity, intra and inter assay precision, recovery rate, linearity between 1 step and 2 step method (45 min. and 60 min.). Results: Both of 45 minutes and 60 minutes test showed 0.1 ng/mL sensitivity. In 45 minutes test, the intra assay coefficients of variation were 3.05%, 3.43%, 1.68%. Also, inter assay coefficients of variation were 3.91%, 2.38%, 0.82%. In 60 minutes test, the intra assay were 5.00%, 3.69%, 1.97%, inter assay were 3.14%, 3.71%, 1.85%.The correlation coefficient of each 2 step and 1 step (45 min.), 2 step and 1 step(60 min.), 1 step (45 min.) and 1 step (60 min.) were y=0.9293x+2.7356 ($R^{2}=0.9999$), y=0.9193x+4.1002 ($R^{2}=0.9993$), y=0.9894x+1.3805 ($R^{2}=0.9997$). Conclusion: Compared 1step method to 2 step method, both method showed very reasonable precision, recovery rate and correlation coefficient. Also, 1 step method(45 min.) of correlation coefficient ($R^2$) was 0.999. We suggest that 1 step method test can reduce the test time and is useful for AFP test.

핵의학 영상검사 후 시행된 핵의학 검체검사에서의 영향

문기춘,권원현,김정인,이인원,Moon, Ki Choon,Kwon, Won Hyun,Kim, Jung In,Lee, In Won 대한핵의학기술학회 2014 핵의학 기술 Vol.18 No.1

핵의학과 영상검사 후에 검체검사를 시행할 경우 결과값에 미치는 영향을 알아보기 위해 PET-CT, Gated Myocardial SPECT, DTPA GFR Scan을 시행하기 전 후에 채혈하여 Tumor marker (AFP,CEA,CA19-9), Hormone (TSH,T3,TG,TG Ab)검사를 시행하여 Difference를 구하였다. 대부분의 결과가 10% 이내의 차이를 나타냈지만 Table 7의 sample 2와 Table 8의 sample 1, sample 6, sample 8의 저 농도 값에서 20%를 넘는 차이를 나타내는 경우가 있었다. 그렇지만 cpm값은 Table 7의 sample 2는 984(전), 1057(후) Table 8의 sample 1은 243(전), 301(후) sample 6은 58(전), 64(후) sample 8은 258(전), 203(후)으로 매우 흡사한 값을 나타냈다. 이 같은 값을 바탕으로 볼 때 영상검사를 시행한 후에 검체검사를 시행하더라도 결과값에 미치는 영향은 없는 것으로 판단된다. Purpose: At our hospital blood is collected from a patient before an imaging test, with the concern of any effect possible when a nuclear medicine imaging test and an in-vitro test are carried out at the same time. However, occasionally, the blood collection is performed after an imaging test, with the reasons that the patient is not properly guided or the patient doesn't follow the guide correctly. In that case, we prefer to gather blood again after a few days. The purpose of this study is not only to see whether there is any effect of an imaging test on the result of the in-vitro test performed with the blood collected after the imaging test, but also to study how many days waiting after each test is appropriate to take a blood sample, if the effect exists. Materials and Methods: From September to October 2013, blood were collected from 13 patients in our hospital regardless of age and sex each time before and after the injection of the radioactive isotope from the tests : PET-CT, Gated Myocardial SPECT, and DTPA GFR Scan. Considering a half-life, AFP, CA19-9, CEA, TSH, and T3 were carried out right after the blood collection. In case of an iodine therapy, blood were taken each time before and after taking radioactive iodine, and, after AFP, CA19-9, and CEA, the difference between them in consistency and in cpm were compared. Results: With 10 patients after the imaging tests and 3 patients after the iodine therapy, their serum cpm was over 10,000. Over time, the cpm decreased in accordance with the half-life ($^{18}F$ 110minutes, $^{99}mTc$ 6hours, $^{201}Tl$ 72hours, $^{131}I$ 7days). Between the two cases, one before and the other after the injection of the radioactive isotope, the cpm and the results of AFP, CA19-9, CEA, TSH, and T3 from three patients each test, PET-CT, Gated Myocardial SPECT, and DTPA GFR Scan, were very similar. In addition, in case of an iodine therapy, there was also not a meaningful difference in the cpm and the results of AFP, CA19-9, and CEA, from three patients in an iodine therapy, between the two cases, one before and the other after taking the radioactive iodine. Conclusion: In case a blood collection was performed after the imaging test which required a radioactive isotope injection, the cpm increased, differently according to the kind of the radioactive isotope. However, the results of the in-vitro tests like AFP, CA19-9, CEA, TSH, T3, etc were nearly not affected. As the result, it's considered that there will not be any significant effect also from other tests, as the result from the performed seven tests.

유방암 수술환자가 Tamoxifen복용기간 중 발생하는 FSH와 E2의 수치 변화

권원현,문기춘,김혜숙,이인원,신숙희,Kwon, Won-Hyun,Moon, Ki-Choon,Kim, Hye-Sook,Lee, In-Won,Shin, Suk-Hee 대한핵의학기술학회 2010 핵의학 기술 Vol.14 No.2

Purpose: As many patients often showed the value of menopause although they were women of childbearing age, this study looked into their previous history. According to the findings, they were patients with a mastectomy due to breast cancer and were taking breast cancer treatment Tamoxifen (the women hormone inhibitor) after chemotherapy. This study is conducted to examine changes in FSH and E2 concentration of patients breast cancer patients of childbearing age according to Tamoxifen used to prevent recurrence of breast cancer and proliferation of mammary parenchyma. Materials and Methods: This study aims to investigate similarity in patients treated with surgery who were in their childbearing age and in values of FSH and E2 by dividing test results of FSH and E2 requested at the department of nuclear medicine among patients who visited this hospital from Jan. 2009 to Mar. 2010 into women of childbearing age (n=50), menopausal women (n=50), and patients with breast cancer surgery who take Tamoxifen (n=50) and then comparing the test results. Results: The FSH and E2 test results of 50 patients were compared and analyzed as average${\pm}$standard deviation, and the results showed that the figure of women of childbearingage (n=50) was FSH : $7.14{\pm}6.19$, E2 : $138.76{\pm}85.40$, that of menopausal women (n=50) was FSH : $52.12{\pm}24.43$, E2 : $15.06{\pm}4.43$, and that of patients with breast cancer surgery who were in their childbearing age (n=50) was FSH : $44.21{\pm}21.07$, E2 : $13.53{\pm}4.26$. When these different results of FSH and E2 were compared, the value of patients with breast cancer surgery who were in their childbearing age with Tamoxifen was somewhat similar to that of menopausal women. Conclusion: The test results of FSH and E2 have reportedly found the test values of patients with breast cancer surgery could be similar to that of menopausal women eventhough they were in their childbearing age due to the women hormone inhibitor Tamoxifen. Therefore, if a tester conducts this experiment after understanding the clinical meaning, the reliability of the tester reporting test results would be increased.

성조숙증 여아들의 임상적 특징 및 진단별 성선자극호르몬 분비호르몬 GnRH (Gonado Tropin Releasing Hormone) 검사결과의 비교분석평가

김정인,권원현,문기춘,이인원,Kim, Jung-In,Kwon, Won-Hyun,Moon, Ki-Choon,Lee, In-Won 대한핵의학기술학회 2016 핵의학 기술 Vol.20 No.2

Purpose Precocious Puberty is defined as the development of secondary sexual characteristics in girls younger than 8 years, and boys 9 years. Cause premature closure of the epiphysis is a disease that eventually decreases the final adult height. In this study, we retrospectively analyzed to evaluate the diagnostic difference the GnRH (Gonado-tropin-releasing Hormone) stimulation test results with medical records of precocious puberty in girls. Materials and Methods From February 2015 to December 2015 it was enrolled in the girls 118 people who visited the Seoul National University Bundang Hospital, Pediatrics, Endocrinology Internal Medicine. True precocious puberty group (n=57), early puberty group (n=39), were divided into Premature thelarche (n=22) group. A Tanner stage, chronological age, bone age, height, body weight for each group was determined by examining the mean${\pm}$standard deviation. GnRH test result was compared LH (Basal, 30 min, 45 min, 60 min), FSH (Basal, 30 min, 60 min) for each group, Each group LH, FSH Peak value distribution, the mean${\pm}$standard deviation was calculated for the peak LH/LH basal ratio, peak LH/Peak FSH ratio. The significance probability (P-value) between the value of each third group was determined. Results The average height of the true precocious puberty group $131{\pm}14.85$, the mean weight was $28.80{\pm}4.93$, the average chronological age $7.1{\pm}0.81$, the mean bone age was $9.9{\pm}0.9$, The average height of early puberty group was $134{\pm}5.10$, the average weight $28.50{\pm}4.43$, the average chronological age $8.05{\pm}0.03$, the mean bone age was $10.0{\pm}0.62$, The average height of Premature thelarche $129{\pm}6,01$, the average weight was $28.65{\pm}5.98$, the average chronological age $7.02{\pm}0.58$, the mean bone age was $8.04{\pm}1.29$. There was no significant difference when compared to the height and weight. There was a significant difference between the groups in the chronologic age and bone age difference (P <0.0002) True precocious puberty group showed peak LH levels at 30'(82.5%), 45'(12.3%), 60'(5.3%), in Peak FSH 30'(8.8%), 60'(91.2%). Early Puberty group showed high values in Peak LH at 30'(79.5%), 45'(17.9%), 60'(2.6%), in peak FSH levels at 30'(7.7%), 60'(92.32%). In Premature thelarche Group it showed the Peak LH levels at 30'(30%), 45'(59%), 60'(9.09%), Peak FSH levels at 30'(0%) 60'(100%). When compared with the The Peak LH/basal LH ratio, True precocious puberty group was $19.09{\pm}17.15$, early puberty group was $15.23{\pm}10.88$, Premature thelarche group showed significant differences between the three groups as $4.93{\pm}4.36$.(P <0.0001) LH Peak/FSH Peak ratio, true precocious puberty group was $1.222{\pm}0.77$, early puberty group was $1.34{\pm}1.23$, Premature thelarche group showed significant differences between the three groups as $0.3{\pm}0.09$(P <0.0001) Conclusion In order to diagnose the true precocious puberty have a diagnostic value when the LH peak after GnRH stimulation is increased by more than two to three times compared to baseline or a predetermined level or more than 5~10 IU/L increases. GnRH Test is a test for a long time and the patient discomfort due to repeated blood sampling, but the hypothalamus-pituitary gland- gonad axis activity evaluate and is the most basic accurate test in the differential diagnosis of precocious puberty disorders. 1. 목적 성조숙증은 2차성징의 발달이 여아에서는 8세 이전 남아에선 9세 이전에 조기 2차성징이 출현하는 증상으로 골단의 조기 폐쇄를 일으켜 결국 최종 성인 신장의 감소를 가져오는 질환이다. 본 연구는 성조숙증으로 내원한 여아들의 GnRH(Gonado-tropin-releasing Hormone) 자극검사 결과와 의무기록을 후향 분석하여 진단별 차이를 알아보고자 하였다. 2. 방법 2015년 2월부터 2015년 12월까지 분당서울대병원 소아청소년 내분비내과를 내원한 여아 118명을 대상으로 하였다. 의무기록을 후향 분석하여 대상 환아들은 진성 성조숙증(true precocious puberty) 57명, 조기사춘기(early puberty) 39명, 유방 조기발육군(premature thelarche) 22명을 진단별로 분류하였다. 진단 당시의 신장, 체중, Tanner stage, 골연령, 역연령, 부모의 키, GnRH 검사에서 LH, FSH와 E2 (Estradiol) Basal 값도 함께 조사하였다. 성선 자극호르몬 결과값 LH (Basal,30min,45min,60min) FSH(Basal,30min,60min)을 비교하여 각 그룹별 LH, FSH Peak치 분포도와 LH 최고치/LH 기저치 비율에 대한 평균${\pm}$표준편차와 LH 최고치/FSH 최고치 비율에 대한 평균${\pm}$표준편차를 비교하여 각 3그룹 간 유의확률(P-value) 값을 구하였다. 골연령의 측정은 Greulich-Pyle법(왼쪽 수근골 X선 사진을 촬영하여 골성숙도를 평가하는 방법- 6개월 단위의 표준손목사진을 보고 비교해서 골연령을 유추하는 방식)을 이용한 소아 청소년 내분비내과 교수가 직접 판독한 결과로 사용하였고 GnRH 검사는 합성 LHRH 100 ug을 정맥 주사하여 LH는 Basal, 30분, 45분,60분 후에 채혈된 결과값과 FSH는 Basal, 30분, 60분후에 채혈된 결과값을 조사하였다. 3. 결과 진성성조숙증그룹의 평균 키는$131{\pm}14.85$, 평균체중은 $8.80{\pm}4.93$, 평균역연령은 $7.1{\pm}0.81$, 평균 골연령은 $9.9{\pm}0.9$, 조기사춘기 그룹의 평균키는 $134{\pm}5.10$, 평균체중은 $28.50{\pm}4.43$, 평균역연령은 $8.05{\pm}0.03$, 평균 골연령은 $10.0{\pm}0.62$, 유방조기발육군의 평균 키는 $129{\pm}6,01$ 평균체중은 $28.65{\pm}5.98$, 평균역연령은 $7.02{\pm}0.58$ 평균 골연령은 $8.04{\pm}1.29$로 세 그룹간에 키와 체중 비교 시 유의한 차이가 없었고 역연령(P < 0.0001), 골연령( P< 0.0001), 골연령과 역연령과의 차이(P < 0.0002 )에서는 그룹간 유의한 차이가 있었다. 각 그룹별 LH, FSH Peak치 분포도 비교시 진성성조숙증 그룹은 LH 30분-82.5%, 45분-12.3%, 60분-5.3%, FSH 30분-8.8%, 60분-91.2%로 높은 Peak치를 보였고 조기사춘기 그룹은 LH 30분-79.5%, 45분-17.9%, 60분-2.6%, FSH 30분-7.7%, 60분 -92.32%로 높은 Peak치를 나타내었다. 유방조기 발육군 그룹에서는 LH 30분-30%, 45분-59%, 60분-9.09%, FSH 30분 -0%, 60분-100%로 Peak치를 나타내었다. LH Peak/LH basal ratio 비교시 진성성조숙증 그룹은 $19.09{\pm}17.15$, 조기사춘기 그룹은 $15.23{\pm}10.88$ 유방조기 발육군 그룹은 $4.93{\pm}4.36$으로 3 그룹간 유의한 차이를 보였다(P < 0.0001). LH Peak/FSH Peak ratio 비교시 진성성조숙증 그룹은 $1.222{\pm}0.77$, 조기사춘기 그룹은 $1.34{\pm}1.23$ 유방조기 발육군 그룹은 $0.3{\pm}0.09$로 3 그룹간 유의한 차이(P < 0.0001)를 보였다. 4. 결론 여아들의 진성성조숙증을 진단하기 위한 GnRH Test 검사는 자극 후 30분과 60분 사이에 LH 최고치가 기저치에 비해 2~3배 이상 증가 되어 있거나 또는 5~10 IU/L 이상 증가되었을 때 유용한 판정 자료로 이용 될 수

이차성 고혈압 환자에서 알도스테론/혈장 레닌활성도 비율을 이용한 원발성 알도스테론증의 진단 및 임상적 유용성 평가

김혜숙,권원현,문기춘,이인원,Kim, Hye-Sook,Kwon, Won-Hyun,Moon, Ki-Choon,Lee, In-Won 대한핵의학기술학회 2008 핵의학 기술 Vol.12 No.2

목적 : 고혈압은 뚜렷한 원인을 찾을 수 없는 본태성고혈압과 다른 원인에 의한 이차성 고혈압으로 크게 나눌 수 있다. 이차성 고혈압은 원인 질환을 알고 치료하면 치유가 가능한 고혈압으로써 고혈압 환자 중에서 비교적 흔히 발생되는 것으로 보고되고 있다. 본 연구는 임상에서 원발성 알도스테론증으로 진단된 이차성고혈압 환자군이 알도스테론/레닌의 비율을 산출하였을 때 이 비율이 정상군보다 얼마나 비정상적으로 증가되어 있는지 또한 본태성고혈압 환자군과는 얼마나 차이가 있는지를 알아보고자 한다. 실험재료 및 방법 : 2006년 4월부터 2008년 3월까지 분당 서울대병원에 내원하여 알도스테론과 레닌활성도를 검사한 환자들(n=901)을 대상으로 하였다. 크게 3그룹으로 분류하여 정상군(n=147), 본태성 고혈압환자군(n=709), 원발성 알도스테론증 환자군(n=45)에 대한 알도스테론, 레닌, 알도스테론/레닌의 비율에 대한 평균${\pm}$표준편차를 측정하였고, 각 그룹간 비교분석에서 유의확률(p-value)값을 구하였다. ROC 곡선을 이용하여 알도스테론/레닌 비율의 기준치(Cut off)에 따른 민감도와 특이도를 구하였다. 결과 : 각 그룹간 알도스테론, 레닌, 알도스테론/레닌 비율의 평균${\pm}$표준편차를 비교하여 보았을 때 정상군(n=147)에서는 알도스테론 : $87.40{\pm}52.81$, 레닌 : $3.16{\pm}5.35$, 알도스테론/레닌 비율 : $52.88{\pm}52.46$로 측정되었고, 본태성 고혈압환자군(n=709)에서는 알도스테론 : $132.39{\pm}83.59$, 레닌 : $2.71{\pm}3.37$, 알도스테론/레닌 비율 : $171.04{\pm}291.56$로 측정되었고, 원발성 알도스테론증으로 진단받은 환자군(n=45)에서는 알도스테론 : $342.48{\pm}229.30$, 레닌 : $0.24{\pm}0.29$, 알도스테론/레닌 비율 : $2325.74{\pm}2200.88$로써 상당히 높게 측정되었다. 알도스테론/레닌 비율의 그룹 간 비교에서는 원발성 알도스테론증의 환자 그룹과 정상그룹, 본태성 고혈압환자그룹 사이에서 p<0.001로써 각각 유의한 차이가 있음을 보였고, 원발성 알도스테론증을 선별함에 있어 ROC 곡선상에서 알도스테론/레닌 비율의 기준치는 Cut off : 485일 때 민감도 : 91.1%, 특이도 : 92.4%를 보였다. 결론 : 아직 표준화된 알도스테론/레닌 비율의 기준치가 정립화 되어 있는 것은 아니지만 본 연구를 통해서 원발성 알도스테론증 환자군은 정상군에 비해서 알도스테론/레닌의 비율이 상당히 높게 증가된다는 것을 알 수 있었고 이는 부신선종(adenoma)으로 인해 알도스테론이 만성적으로 과잉 분비되어 억제된 레닌 활성도를 보이는 것을 의미하고 있다. 즉 알도스테론/레닌 비율의 검사는 임상에서 원발성 알도스테론증을 진단함에 있어 임상적으로 유용하게 사용될 수 있을 거라 생각되어진다. Purpose: To study of difference among primary aldosteronism patients and normal groups and essential hypertension patients and to confirm aldosterone/plasma renin activity ratio increase in secondary hypertension group which was diagnosed as primary aldosteronism. Materials and method: 1. Period: from April 2006 to March 2008. 2.Targets: 901 patients who visited seoul national university bundang hospital. 3. Groups: we divided by three groups. (normal group (n=147), essential hypertension (n=709), primary aldosteronism (n=45)) 4. Then calculated aldosterone/plasma renin activity ratio. 5. We used ROC curve to measure sensitivity and specificity. Results: 1. normal groups aldosterone/plasma renin activity ratio: $52.8{\pm}52.46$ essential hypertension patients aldosterone/plasma renin activity ratio: $171.04{\pm}291.56$ primary aldosteronism patients aldosterone/plasma renin activity ratio: $2325{\pm}2200$. 2. Aldosterone/renin ratio was significant in comparing each groups (p<0.001). 3. The sensitivity was 91.1% and the specificity was 92.4% when cut off of aldosterone/renin ratio was 485. Conclusion: It was confirmed that aldosterone/plasma renin activity ratio in primary aldosteronism was higher than normal group. According to this result, we can tell that aldosterone/ plasma renin activity ratio is very useful in diagnosis of primary aldosteronism.

A형 간염의 자연항체와 예방접종을 통한 항체 생성률의 역가 비교분석

권원현,김경화,조경아,문기춘,김정인,이인원,Kwon, Won Hyun,Kim, Kyung Hwa,Cho, Kyung A,Moon, Ki Choon,Kim, Jung In,Lee, In Won 대한핵의학기술학회 2013 핵의학 기술 Vol.17 No.2

2008년부터 A형 간염 환자들이 급속히 증가하고 본원에 내원하여 건진을 받는 대부분의 수검자들이 A형 간염(IgG) 항체 생성 유무에 관심이 많아지며 검사 건수가 증가하였다. 그에 따라 항체 검사결과가 cut-off값에 걸리는 검체가 많아져 원인을 분석하였더니 대부분 A형 간염 예방접종을 한 수검자들이었다. 이에 저자들은 건강증진센터에서 설문조사를 통하여 자연면역을 획득한 수검자들 그룹과 본원에서 A형 간염 예방접종(1차, 2차)을 실시한 직원들 그룹으로 나누어 검사를 시행하였고 cut-off값을 기준으로 항체 생성률과 그에 대한 역가를 비교하고 진단검사의학과와 핵의학과에서 사용하는 진단 시약간에 항체 생성률과 그에 대한 역가를 비교해 보고자 했고, 2012년 8월 한 달 동안 건진 수검자 185명을 설문조사하여 자연면역을 획득한 119명과 본원에서 예방 접종을 실시한 직원들을 대상으로 1차 접종자 53명, 2차 접종자 59명으로 대상을 분류했다. 항체 생성률은 cut-off값 1을 기준했을 때 0.90-1.10 (${\pm}$), 0.60-0.89 (1+), 0.30-0.59 (2+), 0.01-0.29 (3+)로 나누어 역가를 비교하고, 같은 기준으로 제조사별 백신 접종 후 항체 생성률에 대한 역가를 비교평가 해 보았다. 그 결과, 건진 수검자 중 자연 면역을 획득한 수검자는 cut-off값 1을 기준했을 때, 0.90-1.10 (${\pm}$)가 0%, 0.60-0.89 (1+)가 0%, 0.30-0.59 (2+)가 4.2%, 0.01-0.29 (3+)가 96%로 역가가 <0.60 ($${\geq_-}2+$$)가 100%였다. 그리고 예방접종을 실시한 직원들의 항체 생성률은 1차 접종자 중 ${\pm}$가 59.1%, 1+가 18.1%, 2+가 18.1%, 3+가 4.6%로 총 45.3%였고, 역가는 $${\geq_-}$$ 0.60 ($${\leq_-}1+$$)가 77.3%였다. 2차 접종자의 항체 생성률은 ${\pm}$가 1.9%, 1+가 15.4%, 2+가 36.54%, 3+가 46.2%로 총 88.1%였고 역가는 <0.60 ($${\geq_-}2+$$) 82.7%가 였다. 또한 제조사별로 비교 하였을 때 1차 접종자의 항체 생성률은 BNIBT 20.8% (${\pm}24.5%$), GB 15.7% (${\pm}7.8%$), RIAKEY 94.3% (${\pm}3.8%$), ROCHE 83% (${\pm}0%$), Abbot 73.1% (${\pm}5.8%$)였고, 2차 접종자의 항체 생성률은 BNIBT 86.4% (${\pm}1.7%$), GB 88.5% (${\pm}1.9%$), RIAKEY 100% (${\pm}0%$), ROCHE 98.3% (${\pm}0%$), Abbot 98.2% (${\pm}0%$)였다. 즉 자연면역 항체가 예방접종에 의한 항체보다 역가가 높다는 것을 알 수 있었고, 1차 접종 후 보다는 2차 접종 후 검사를 시행했을 때 항체 생성률과 역가가 대부분 높아짐을 알 수 있었다. 따라서 결과 보고시 negative, index (${\pm}$), weak positive (1+), positive (2+), strong positive (3+)로 역가를 나누어 보고를 하거나 결과값에 index값을 같이 적어서 결과를 상세히 보고한다면 과거결과와 비교도 가능할 것이다. 또 제조사별 비교 시 1차 예방접종 후의 항체 생성률과 역가에서 시약간에 많은 차이를 보이고 있었고, 매년 예방 접종률이 높아지고 있는 시점에서 이러한 차이를 줄이기 위해서 각 제조사들은 민감도나 재현성에 더 주의를 기울여야 하겠고, 자연면역항체와 예방접종을 통한 항체간에 생길 수 있는 미지의 차이를 감안하여 검사자들이 사용하는 시약을 신뢰할 수 있도록 더 연구하고 개발해야 할 것이다. Purpose: Since 2008, hepatitis A patients was rapidly increasing. So, Most of the health checkup examinees were interested in whether hepatitis A antibody was a lot. thereby The number of tests was increasing. In recent years, Antibody test results in the range of cut-off values were increased. According to the cause analysis, most examinees had a hepatitis A vaccine. This study was conducted to classify hepatitis A antibody as natural antibody and antibody after vaccination and compared the titer for seroconversion rate based on cut-off values. Materials and Methods: For a month in August 2012, First, We surveyed 185 health examinees and classified 119 health examinees who had acquired natural antibody. Second, for employees who were inoculated against hepatitis at our hospital, We classified into 53 primary inoculators and 59 secondary inculators. when the standard of cut-off value was 1, The seroconversion rate was compared the titer divided by 0.90-1.10 (${\pm}$), 0.60-0,89 (1+), 0.30-0.59 (2+), 0.01-0.29 (3+) and we compared the titer for seroconversion rate by each manufacturer after vaccination. Results: When the standard of cut-off value was 1, the titer of 119 health examinees who had acquired natural antibody was 0.90-1.10 (${\pm}$): 0%, 0.60-0.89 (1+): 0%, 0.30-0.59 (2+): 4.2%, 0.01-0.29 (3+): 96% and the titer of <0.60 ($${\geq_-}2+$$) was 100%. The titer of 53 primary inoculators was 0.90-1.10 (${\pm}:59.1%$), 0.60-0.89 (1+): 18.1%, 0.30-0.59 (2+): 18.1%, 0.01-0.29 (3+): 4.6% and the seroconversion rate was 45.3%. The titer of $${\geq_-}0.60$$ ($${\leq_-}1+$$) was 77.3%. The titer of 59 secondary inoculators was 0.90-1.10 (${\pm}:1.9%$), 0.60-0.89 (1+): 15.4%, 0.30-0.59 (2+): 36.54%, 0.01-0.29 (3+): 46.2% and the seroconversion rate was 88.1%. The titer of <0.60 ($${\geq_-}2+$$) was 82.7%. When we compared the titer for seroconversion rate by each manufacturer after vaccination, the seroconversion rate of 53 primary inoculators was BNIBT: 20.8% (${\pm}:24.5%$), GB: 15.7% (${\pm}:7.8%$), RIAKEY: 94.3% (${\pm}:3.8%$), ROCHE: 83% (${\pm}:0%$), ABBOTT: 73.1% (${\pm}:5.8%$) and the seroconversion rate of 59 secondary inoculators was BNIBT : 86.4% (${\pm}:1.7%$), GB: 88.5% (${\pm}:1.9%$), RIAKEY: 100% (${\pm}:0%$), ROCHE: 98.3% (${\pm}:0%$), ABBOTT: 98.2% (${\pm}:0%$). Conclusion: The study show that the titer of natural immune antibodies is higher than the titer of vaccination and the titer of secondary inoculation is mainly higher than the titer of primary inoculation. Consequently, if we know the titer of hepatitis A antibodies, it will help to give resullt reports. And then, when we compared the titer and the seroconversion rate by each manufacturer, There was a very distinct difference. As the test subjects inoculate against hepatitis A (HAV), it is considered BNIBT, GB will occur false negative rate and RIAKEY, ROCHE, ABOTT will occur false positive rate.

타액이 편평상피세포암(SCC)과 갑상선기능검사에 미치는 영향

조만익 ( Man Ick Cho ),문기춘 ( Ki Choon Moon ),김혜숙 ( Hea Sook Kim ) 대한임상검사과학회 2004 대한임상검사과학회지(KJCLS) Vol.36 No.2

Squamous cell carcinoma(SCC) associated antigen is a subfraction of TA-4, a tumor-associated antigen first described by Kato and Torigoe in 1977. TA-4, obtained from squamous cell carcinoma cancer tissue of the uterine cervix, has been characterized as a glycoprotein with a molecular weight of approximately 45,000 daltons. SCC antigen has been studied in other squamous cell malignancies including lung, esophagus, head and neck, anal canal, and skin. SCC antigen is shed naturally through sweat, saliva and other body fluids. Contamination of specimens, tray, bead dispenser or other accessories with sweat, saliva or aerosols can cause falsely elevated values. To reduce the possibility of contamination, gloves should be worn in all phases of assay preparation, and when handling specimens, accessories or reagents that will be used in SCC and Thyroid function test(TFT).